Trial Profile
To evaluate the efficacy and safety of Nintedanib in patients with advanced Idiopathic Pulmonary Fibrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2017
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Therapeutic Use
- 20 Jan 2017 New trial record